H1

An antibody therapy developed by Teva Pharmaceuticals and Sanofi to treat inflammatory bowel disease (IBD) has been shown in a mid-stage clinical trial to be potentially more effective than the competition. Nearly half of ulcerative colitis patients given a high dose of the drug saw their symptoms resolve after 14 weeks compared to 20% of patients on placebo. Similarly, nearly half of the Crohn’s disease patients on a high dose regimen experienced meaningful improvement on a measure of disease severity compared to 13% of patients on placebo. Learn more: https://hubs.la/Q02_Z3__0 #teva #sanofi #ibd #ibs #duvakitug

Happy Holidays from all of us at H1! This holiday season, we hope you’re able to rest and enjoy time with loved ones. We wish you peace, health, and joy – and a bright year to come! #happyholidays #holidaycheer #seasonsgreetings #merryandbright

We’re proud to be participating in #FierceJPMWeek 2025 as we anticipate an incredible start to the year! Our CEO & Co-founder Ariel Katz will be joining a panel of inspirational healthcare leaders to discuss the topic of “Unlocking the Power of Healthcare Data: Advancing Access and Connectivity to Drive Patient Outcomes.” We’ll explore the challenges and opportunities in democratizing healthcare data, with a focus on integrated solutions and strategies that address data fragmentation and enable swift access to diverse patient and provider demographics. Learn more: https://lnkd.in/eZBPTdbM #FierceJPM #JPMWeek2025 #healthcaredata

When disaster strikes, every second counts. Advanced technologies can play a vital role in assisting governments, nonprofits and first responders to act quickly and decisively. At H1, we’ve witnessed this first-hand, as thousands of healthcare professionals use our #H1Connect platform to connect with NGOs to provide humanitarian aid around the world. Our CEO Ariel Katz underscores how this new generation of tools, including #AI and digital platforms, can be leveraged to create a dynamic system and align crisis needs with the right personnel. Read his insights in Forbes Technology Council: https://hubs.la/Q0302-pR0 #HumanitarianAid #CrisisCoordination #MedicalAid #DisasterResponse #ForbesTechCouncil

Incyte's diversity-focused leaders are improving patient representation in clinical trials by implementing the right tools and the right data to support their decision-making. Dija A. and Stacy Eckstein, MS recently spoke with us about how H1 helps them review their progress in real-time: “In my role, I rely heavily on internal and external data to objectively identify sites that have access to diverse patient populations.” Stacy said. Hear more about how the Incyte team stays nimble and targeted as they work toward their enrollment goals. Watch the interview: https://hubs.la/Q02_RbjZ0 #incyte #claimsdata #diversitydata #healthtech #healthcaretechnology #patientenrollment

To further our mission of connecting the world to the right doctors, our H1 Connect solution bridges the gap between HCPs and NGOs to ensure that humanitarian aid can reach people in need at the right time. We recently had the opportunity to work with Global Response Medicine to help them identify qualified, willing, and available doctors for a trauma surgery skills course in Ukraine. To learn more about how we were able to support their mission, download the case study: https://hubs.la/Q02_YvGy0 #globalresponsemedicine #grm #humanitarianefforts #humanitarianaid #emergencyrosters #readyreserve

We look forward to participating in the Longwood Healthcare Leaders #SanFranciscoCEO gathering early next year! Each year, we gain invaluable insights from the many healthcare leaders who attend. Our CEO & Co-founder Ariel Katz will be moderating a panel discussion on the topic of Patient-Centric Development. A big thank you to Longwood Healthcare Leaders for the opportunity to take part in this event! https://hubs.la/Q02_W80B0 Longwood Fund #longwoodhealthcareleaders

Identifying the right sites for clinical trials is a critical step toward enrolling the desired patient population and reaching your diversity goals. We had the pleasure of sitting down with two of Incyte's diversity and inclusion leaders, Dija A. and Stacy Eckstein, MS to hear how they’ve used H1’s diversity and claims data to inform their program strategies. See how Incyte is improving patient representation in clinical trials with the right data insights. Watch the full interview: https://hubs.la/Q02_LN1-0 #incyte #healthequity #clinicaltrialdiversity #diversityandinclusion #patientenrollment

There is growing evidence to support the hope that GLP-1 receptor agonists could move beyond the weight loss and diabetes space to bring protection against Alzheimer’s disease. Two recent studies from Novo Nordisk show a significant reduction in risk of Alzheimer’s disease diagnosis in type 2 diabetes patients taking semaglutide and a slower decline in cognitive function among patients taking liraglutide. Novo intends to release results from a Phase III study next year. Learn more: https://hubs.la/Q02-YBQ-0 #alzheimers #semaglutide #liraglutide #glp1 #novonordisk #dementia

As clinical trial diversity guidance continues to be rolled out globally, we’re asking life sciences companies how they’re getting ready. We had the pleasure of speaking with two of Incyte's diversity leaders – Dija A. and Stacy Eckstein, MS to learn about their strategy to promote diversity and inclusion in clinical trials, and to understand how technology plays a key role in that process. Keep an eye out for the full interview coming next week! #incyte #clinicaltrialdiversity #sitefeasibility #healthtech #healthcareinnovation #healthequity